- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05217810
Atectura®에 대한 실제 환경에서의 24주 전향적, 오픈 라벨, 다기관, 단일 암 rPMS 연구
Atectura®(QMF149 150/80 μg o.d., QMF149 150/ 160μg OD 및 QMF149 150/320μg OD Breezhaler 사용)
This surveillance was designed as a prospective, open-label, multicenter, single-arm, non-interventional, observational study to evaluate the safety and effectiveness of Atectura inhalation capsule for up to 24 weeks under routine clinical practice.
연구 개요
상태
정황
상세 설명
The three different doses of Atectura inhalation capsule via Breezhaler will be prescribed according to the approved label information in Korea, and the investigation for any additional diagnostic or monitoring will be not conducted for this study
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Busan, 대한민국, 48108
- Novartis Investigative Site
-
Gyeongsangnam Do, 대한민국, 51353
- Novartis Investigative Site
-
Jeju City, 대한민국, 63241
- Novartis Investigative Site
-
Seoul, 대한민국, 05505
- Novartis Investigative Site
-
Seoul, 대한민국, 04763
- Novartis Investigative Site
-
Seoul, 대한민국, 06273
- Novartis Investigative Site
-
Seoul, 대한민국, 137 707
- Novartis Investigative Site
-
Taegu, 대한민국, 41944
- Novartis Investigative Site
-
Ulsan, 대한민국, 44033
- Novartis Investigative Site
-
-
Dalseo gu
-
Daegu, Dalseo gu, 대한민국, 42602
- Novartis Investigative Site
-
-
Gangneung si
-
Kangwon Do, Gangneung si, 대한민국, 210 711
- Novartis Investigative Site
-
-
Gangwon-do
-
Wŏnju, Gangwon-do, 대한민국, 26426
- Novartis Investigative Site
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, 대한민국, 10380
- Novartis Investigative Site
-
Guri-si, Gyeonggi-do, 대한민국, 11923
- Novartis Investigative Site
-
-
Gyeongsangnam-do
-
Jinju, Gyeongsangnam-do, 대한민국, 52727
- Novartis Investigative Site
-
-
Jeollabuk-do
-
Jeonju, Jeollabuk-do, 대한민국, 54907
- Novartis Investigative Site
-
-
Jeonlabuk Do
-
Iksan Si, Jeonlabuk Do, 대한민국, 54538
- Novartis Investigative Site
-
-
Korea
-
Daejeon, Korea, 대한민국, 35015
- Novartis Investigative Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
subjects who received at least one dose of Atectura inhalation capsule via Breezhaler and that have provided consent for their data collection.
설명
Inclusion Criteria:
- Adolescent (≥12 years of age) and adult patients with a physician's diagnosis of asthma, who are prescribed Atectura inhalation capsule (indacaterol acetate/mometasone furoate; 150/80, 150/160, 150/320 μg) via Breezhaler, as per the approved label information
- Patients who participate in the study after signing the consent form for data collection and use (Data Privacy ICF) after receiving a clear explanation of the objectives and nature of the study from the investigator (For patients under the age of 18, consent and signature of a legal representative is required)
Exclusion Criteria:
- Patients who are contraindicated for this medicinal product as described in the Precautions for Use in the label information (package insert) A. Patients with hypersensitivity reaction to this medicinal product or any of its constituents B. Because this medicinal product contains lactose, patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption, etc.
- Patients with acute asthma symptoms, including acute episodes of bronchospasm, for which a short-acting bronchodilator is required
- Patients participating in other interventional clinical trials
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Atectura inhalation capsule (150/80ug)
Indacaterol acetate/Mometasone furoate; 150/80ug |
There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled. |
|
Atectura inhalation capsule (150/160ug)
Indacaterol acetate/Mometasone furoate; 150/160ug |
There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled. |
|
Atectura inhalation capsule (150/320ug)
Indacaterol acetate/Mometasone furoate; 150/320ug |
There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of adverse events and serious adverse events
기간: 24 weeks
|
Incidence of AE and SAE will be collected |
24 weeks
|
|
Incidence of unexpected adverse events and unexpected serious adverse events
기간: 24 weeks
|
Incidence of unexpected AE and SAE will be collected. The term "unexpected" means not listed in local label |
24 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
change from baseline in trough FEV1
기간: Baseline, week 12
|
Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. |
Baseline, week 12
|
|
change from baseline in ACT score
기간: Baseline, week 12
|
The Asthma Control Test (ACT) is a validated tool to assess overall asthma control. It is a 1 page questionnaire consisting of 5 simple questions assessing: asthma symptoms, use of rescue medications, and the impact of asthma on everyday functioning. All questions are scored on a 5-point Likert scale, with a higher score indicating better control. All scores are added together to calculate a total score. Total score ranges from 5 to 25. A positive change indicates improvement. |
Baseline, week 12
|
|
Effective rate and ineffective rate by investigator assessment
기간: week 12
|
Effective (improved) rate and ineffective (unchanged/aggravated) rate by investigator assessment |
week 12
|
|
Baseline characteristics of patients showing adverse events/adverse drug reactions
기간: 24 weeks
|
The incidence rates of AEs/ADRs will be presented by factors, such as subject baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. above 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations. |
24 weeks
|
|
Baseline characteristics of patient in relation to changes from baseline through FEV1 and ACT score
기간: 12 weeks
|
Regression analysis will be performed to determine factors affecting the change in trough FEV1 and ACT score, out of baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations |
12 weeks
|
|
Baseline characteristics of patients in relation to the investigator assessment
기간: 12 weeks
|
Logistic regression analysis will be performed to determine factors affecting the effectiveness (improved) in the investigator assessment, out of baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. above 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations. |
12 weeks
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Novartis Pharmaceuticals, Novartis Pharmaceuticals
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .